ClinicalTrials.gg
Not yet recruitingNCT07572123Updated Nov 18, 2026

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

A Phase 2/3 interventional study of 3-Dimensional Conformal Radiation Therapy and Autologous Hematopoietic Stem Cell Transplantation in Recurrent Classic Hodgkin Lymphoma and Refractory Classic Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI). Not yet recruiting. Open to participants aged 5 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2/3, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
5 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Planned enrollment
7th of 80
374 · median 52
Started
2026
the only one that year
Phase 2/3
3 of 80
3 open now
Primary completion
2029-03
later than 22 of 27 live
Registered
80th of 80
by date
Lead sponsor
6 of 80
National Cancer Institute (NCI)

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 22 of the 27 other live ones, and was the 80th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 5 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). In addition, the phase III trial will compare the effect of pembrolizumab after HDT-ASCT to standard of care HDT-ASCT alone in high-risk patients with relapsed or refractory classic Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. An ASCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving HDT before an ASCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Radiation therapy (RT) uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving brentuximab vedotin and nivolumab after radiation may be safe, tolerable and more effective than standard of care HDT-ASCT in treating patients with standard risk relapsed or refractory classic Hodgkin lymphoma. In addition, giving pembrolizumab after standard of care HDT-ASCT may be safe and tolerable and more effective than HDT-ASCT alone in treating high-risk patients with relapsed or refractory classic Hodgkin lymphoma.

Read the detailed description

PRIMARY OBJECTIVES:

I. Demonstrate the non-inferiority (and possible superiority) in progression free survival (PFS) amongst patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after checkpoint inhibitor-based maintenance and localized radiation in comparison to standard of care HDT-ASCT. (Phase III Standard-Risk) II. Demonstrate the superiority of checkpoint inhibitor-based maintenance after HDT-ASCT in improving PFS among patients with R/R cHL in comparison to standard of care HDT-ASCT. (Phase II High-Risk)

SECONDARY OBJECTIVES:

I. To assess overall survival (OS) in the treatment arms in the standard risk as well as high-risk groups.

II. To assess safety and toxicity of the treatment regimens in the standard risk as well as high risk groups.

EXPLORATORY OBJECTIVES:

I. To evaluate prognostic factors (lactate dehydrogenase [LDH], erythrocyte sedimentation rate [ESR], time to relapse, B symptoms, extranodal disease, stage, bulk, treatment with a checkpoint inhibitor, response at the time of ASCT) associated with risk of progression following HDT-ASCT (Arms B and D).

II. To compare the impact of various radiation therapy modalities utilized (e.g., 3-dimensional conformal radiation therapy [3D-CRT], intensity-modulated radiation therapy [IMRT], proton therapy) and its association with dosimetric and clinical outcomes, including toxicity assessment, (grade 2+), at the end of radiation.

III. To assess PFS for patients in partial metabolic response (PMR) receiving radiation therapy, compared to those patients in complete metabolic response (CMR), for all arms of the study.

OUTLINE: Patients in the standard risk cohort are assigned to Arm S and patients in the high risk cohort are assigned to Arm H.

ARM S: Patients receive standard of care salvage therapy for up to 2-4 cycles per investigator choice. After completing salvage therapy, patients without stable disease (SD) or progressive metabolic disease (PMD) are randomized to Arm A or Arm B.

ARM A: Patients undergo photon RT with either 3DCRT, IMRT, volume modulated arc therapy (VMAT), or tomotherapy or proton RT with either passive scattering, uniform scanning, or pencil beam scanning over 15-17 fractions. Starting 4-8 weeks after completing radiation therapy, patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab for an additional 2 cycles in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive HDT and undergo ASCT per standard of care in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment with brentuximab vedotin for up to 16 cycles in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization.

ARM H: Patients receive 2-4 cycles of standard of care salvage therapy per investigator choice. After completing salvage therapy, patients without SD or PMD are randomized to Arm C or Arm D.

ARM C: Patients receive HDT and undergo ASCT per standard of care. Starting 4-8 weeks after transplant, patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment with brentuximab vedotin for up to 16 cycles in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization.

ARM D: Patients receive HDT and undergo ASCT per standard of care in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment as in arm B in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization.

Additionally, patients may undergo blood sample collection, computed tomography (CT), and positron emission tomography (PET)/CT throughout the study.

After completion of study treatment, patients are followed every 6 months for the first 2 years then annually for up to 15 years.

03

Conditions studied

  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
5 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • STEP 0 REGISTRATION: Patient must have confirmed classical Hodgkin lymphoma
  • STEP 0 REGISTRATION: Patient must be 5-75 years of age
  • STEP 0 REGISTRATION: Patient must have relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after of chemotherapy
  • STEP 0 REGISTRATION: Patients > 17 years of age must have an (ECOG) performance status 0-2 and patients ≤ 17 years of age must have a Lansky performance status 50-100
  • STEP 0 REGISTRATION: Patient must have had a PET CT or magnetic resonance imaging (MRI) (PET1) confirming relapse. The PET1 must have been completed prior to starting any salvage therapy and must be obtained within 56 days prior to Step 0 registration

    • NOTE: If patient received one cycle of salvage prior to study enrollment, PET1 confirming relapse must have been completed prior to the initiation of any salvage therapy
  • STEP 0 REGISTRATION: Patient must be considered standard- or high-risk at the time of initial relapse. If a patient meets one the following criteria below, they are considered high risk:

    • Primary refractory disease to frontline therapy
    • Relapse in \< 3 months after completion of frontline non- containing therapy
    • Relapse in \< 6 months after completion of frontline checkpoint inhibitor containing therapy
    • > 4 disease sites at relapse (as defined by the German Hodgkin Study Groups [GHSG] Criteria)
    • Prior radiation that would result in overlapping fields that would exceed the RT dose to critical organs. For additional questions, contact the radiation oncology study co-chairs
    • Patients with bone marrow involvement

      • Patients who do not meet the criteria above are considered standard risk
  • STEP 0 REGISTRATION: Patient must be considered eligible for high dose chemotherapy and hematopoietic cell transplant
  • STEP 0 REGISTRATION: Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

    • All patients of must have a blood test or urine study within 14 days prior to Step 0 registration to rule out pregnancy
    • A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:

      • Has achieved menarche
      • Has not undergone a hysterectomy or bilateral oophorectomy
      • Has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • STEP 0 REGISTRATION: Patient must not expect to conceive or father children by using accepted and effective method(s) of or by abstaining from sexual intercourse for the duration of their participation in the study
  • STEP 0 REGISTRATION: Patient must have the ability to understand and the willingness to sign a written document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
  • STEP 0 REGISTRATION: (ANC) ≥ 1,000/mm\^3 (≤ 14 days prior to Step 0 registration)
  • STEP 0 REGISTRATION: ≥ 100,000/mm\^3 (≤ 14 days prior to Step 0 registration)
  • STEP 0 REGISTRATION: Total ≤ 2 x institutional (ULN) (≤ 14 days prior to Step 0 registration)
  • STEP 0 REGISTRATION: (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 x institutional ULN (≤ 14 days prior to Step 0 registration)
  • STEP 0 REGISTRATION: Estimated (GFR) (eGRF) ≥ 50 mL/min/1.73 m\^2 for patients > 17 years of age (≤ 14 days prior to Step 0 registration)
  • STEP 0 REGISTRATION: Pediatric patients (\< 17 years old) must have one of the following: (≤ 14 days prior to Step 0 registration)

    • Estimated GFR (eGFR) ≥ 50 mL/min/1.73 m2 using the Bedside Schwartz formula (2009)
    • 24 hour urine ≥ 50 mL/min/1.73 m\^2
    • GFR ≥ 50 mL/min/1.73 m\^2

      • Note: GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard).
    • NOTE: Estimated GFR (eGFR) from cystatin C or other estimates not listed above are not acceptable for determining eligibility
  • STEP 0 REGISTRATION: (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 0 registration are eligible for this trial
  • STEP 0 REGISTRATION: For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • STEP 0 REGISTRATION: Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • STEP 0 REGISTRATION: Patient must not have any current or prior history of central nervous system (CNS) lymphoma
  • STEP 0 REGISTRATION: Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • STEP 0 REGISTRATION: Patients must not have grade 2 or greater peripheral motor sensory neuropathy
  • STEP 0 REGISTRATION: Patient must not have a history of (non-infectious) pneumonitis/interstitial lung disease that required or have current pneumonitis/interstitial lung disease
  • STEP 0 REGISTRATION: Patient must not have the following symptomatic disorders: rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, Sjögren's syndrome, or autoimmune vasculitis (e.g., Wegener's granulomatosis), or conditions of that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone). Patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study

    • Replacement doses of steroids for patients with adrenal insufficiency are allowed
    • Additionally, patients must not have an autoimmune disease that is felt by the treating physician to have the potential to be exacerbated by checkpoint inhibition
  • STEP 1 RANDOMIZATION: Patient must have undergone 2-4 cycles of salvage treatment as part of Step 0 of this protocol
  • STEP 1 RANDOMIZATION: Patients must be considered eligible for high dose chemotherapy and autologous hematopoietic cell transplant
  • STEP 1 RANDOMIZATION: Patient must have had a PET CT (PET2) following 2 cycles of on study salvage therapy and demonstrate complete metabolic response (CMR) or partial metabolic response (PMR). Patients with stable disease/no metabolic response (SD/NMR) or progressive metabolic disease (PMD) are ineligible to proceed to Step 1 randomization
  • STEP 1 RANDOMIZATION: Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (≤ 14 days prior to Step 1 randomization)
  • STEP 1 RANDOMIZATION: Platelets ≥ 75,000/mm\^3 (≤ 14 days prior to Step 1 randomization)
  • STEP 1 RANDOMIZATION: Total bilirubin ≤ 2 x institutional upper limit of control (ULN) (≤ 14 days prior to Step 1 randomization)
  • STEP 1 RANDOMIZATION: AST(SGOT) and ALT(SGPT) ≤ 3.0 x institutional ULN (≤ 14 days prior to Step 1 randomization)
  • STEP 1 RANDOMIZATION: Pediatric patients (\< 17 years old) must have one of the following: (≤ 14 days prior to Step 1 randomization)

    • Estimated GFR (eGFR) ≥ 50 mL/min/1.73 m\^2 using the Bedside Schwartz formula (2009)
    • 24 hour urine creatinine clearance ≥ 50 mL/min/1.73 m\^2
    • GFR ≥ 50 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • NOTE: Estimated GFR (eGFR) from cystatin C or other estimates not listed above are not acceptable for determining eligibility
  • STEP 1 RANDOMIZATION: Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

    • All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy
    • A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • STEP 1 RANDOMIZATION: Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue to use contraceptive measures for 5 months after the last dose of nivolumab and for 4 months after the last dose of pembrolizumab, as well as not breastfeed during these same timeframes
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Arm A (salvage therapy, RT, brentuximab vedotin, nivolumab)

    Patients receive 2-4 cycles of standard of care salvage therapy per investigator choice. Patients undergo photon RT with either 3DCRT, IMRT, VMAT, or tomotherapy or proton RT with either passive scattering, uniform scanning, or pencil beam scanning over 15-17 fractions. Starting 4-8 weeks after completing radiation therapy, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab for an additional 2 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients may undergo blood sample collection, CT, and PET/CT throughout the study.

    Radiation: 3-Dimensional Conformal Radiation Therapy · Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Radiation: Pencil Beam Scanning · Procedure: Positron Emission Tomography · Procedure: Salvage Therapy · Radiation: Scattering Proton Beam Therapy · Radiation: Tomotherapy · Radiation: Uniform Active Scanning Proton Beam Therapy · Radiation: Volume Modulated Arc Therapy

  • Experimental
    Arm B (salvage therapy, HDT-ASCT, RT, brentuximab vedotin[BV])

    Patients receive 2-4 cycles of standard of care salvage therapy per investigator choice. Patients receive HDT and undergo ASCT per standard of care in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment with brentuximab vedotin for up to 16 cycles in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization. Additionally, patients may undergo blood sample collection, CT, and PET/CT throughout the study.

    Radiation: 3-Dimensional Conformal Radiation Therapy · Procedure: Autologous Hematopoietic Stem Cell Transplantation · Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: High Dose Chemotherapy · Radiation: Intensity-Modulated Radiation Therapy · Radiation: Pencil Beam Scanning · Procedure: Positron Emission Tomography · Procedure: Salvage Therapy · Radiation: Scattering Proton Beam Therapy · Radiation: Tomotherapy · Radiation: Uniform Active Scanning Proton Beam Therapy · Radiation: Volume Modulated Arc Therapy

  • Experimental
    Arm C (salvage therapy, HDT-ASCT, pembrolizumab, RT, BV)

    Patients receive 2-4 cycles of standard of care salvage therapy per investigator choice. Patients receive HDT and undergo ASCT per standard of care. Starting 4-8 weeks after transplant, patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment with brentuximab vedotin for up to 16 cycles in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization. Additionally, patients may undergo blood sample collection, CT, and PET/CT throughout the study.

    Radiation: 3-Dimensional Conformal Radiation Therapy · Procedure: Autologous Hematopoietic Stem Cell Transplantation · Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: High Dose Chemotherapy · Radiation: Intensity-Modulated Radiation Therapy · Biological: Pembrolizumab · Radiation: Pencil Beam Scanning · Procedure: Positron Emission Tomography · Procedure: Salvage Therapy · Radiation: Scattering Proton Beam Therapy · Radiation: Tomotherapy · Radiation: Uniform Active Scanning Proton Beam Therapy · Radiation: Volume Modulated Arc Therapy

  • Experimental
    Arm D (salvage therapy, HDT-ASCT, RT, brentuximab vedotin)

    Patients receive 2-4 cycles of standard of care salvage therapy per investigator choice. Patients receive HDT and undergo ASCT per standard of care in the absence of disease progression or unacceptable toxicity. Starting within 4-8 weeks after transplant, patients with CMR may also undergo RT as in arm A over 15-17 fractions and patients with PMR may also undergo RT over 20-22 fractions per investigator. Starting 30-45 days after transplant, patients may also receive maintenance treatment as in arm B in the absence of disease progression or unacceptable toxicity as determined per investigator at time of randomization. Additionally, patients may undergo blood sample collection, CT, and PET/CT throughout the study.

    Radiation: 3-Dimensional Conformal Radiation Therapy · Procedure: Autologous Hematopoietic Stem Cell Transplantation · Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: High Dose Chemotherapy · Radiation: Intensity-Modulated Radiation Therapy · Radiation: Pencil Beam Scanning · Procedure: Positron Emission Tomography · Procedure: Salvage Therapy · Radiation: Scattering Proton Beam Therapy · Radiation: Tomotherapy · Radiation: Uniform Active Scanning Proton Beam Therapy · Radiation: Volume Modulated Arc Therapy

Interventions

  • Radiation3-Dimensional Conformal Radiation Therapy

    Undergo 3DCRT

    Also known as: 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure)

  • ProcedureAutologous Hematopoietic Stem Cell Transplantation

    Undergo ASCT

    Also known as: AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • Given IV

    Also known as: ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35

  • ProcedureComputed Tomography

    Undergo CT and PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • DrugHigh Dose Chemotherapy

    Receive HDT

    Also known as: high-dose chemotherapy

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

    Also known as: IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • BiologicalNivolumab

    Given IV

    Also known as: ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo

  • BiologicalPembrolizumab

    Given IV

    Also known as: BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475

  • RadiationPencil Beam Scanning

    Undergo pencil beam proton RT

    Also known as: PBS, Pencil Beam Proton Scanning

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • ProcedureSalvage Therapy

    Receive standard of care salvage therapy

    Also known as: Rescue Therapy, Salvage

  • RadiationScattering Proton Beam Therapy

    Undergo passive scattering proton RT

    Also known as: Passive Scattering

  • RadiationTomotherapy

    Undergo tomotherapy

    Also known as: helical tomotherapy

  • RadiationUniform Active Scanning Proton Beam Therapy

    Undergo uniform scanning proton RT

    Also known as: Uniform Active Scanning

  • RadiationVolume Modulated Arc Therapy

    Undergo VMAT

    Also known as: VMAT, Volumetric Modulated Arc Therapy (procedure)

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) (Standard risk cohort)

    The analysis will be performed using the repeated confidence intervals methodology. Two-sided repeated confidence interval will be constructed using the partial likelihood estimate from stratified Cox proportional hazards model and the critical value based on the Lan-DeMets error-spending function that corresponds to the truncated O'Brien-Fleming boundaries. Sensitivity analysis will be performed to assess the possible impact of treatment non-compliance. The actual treatment received may be considered in a multivariable Cox model where possible effects of clinical and biological characteristics on outcome are assessed.

    Time frame: From randomization to progression or death without documented progression, assessed up to 15 years

  2. PFS (High-risk cohort)

    Stratified log-rank test will be used for the primary analysis to compare the PFS between arms D and C.

    Time frame: From randomization to progression or death without documented progression, assessed up to 15 years

Secondary outcomes

  1. Overall survival (OS) (Standard risk cohort)

    The analysis will be performed using the stratified log-rank test. To preserve the overall type I error rate, critical values at the interim efficacy analyses will be determined using a truncated version of the Lan-DeMets error spending function corresponding to the O'Brien-Fleming boundary.

    Time frame: From randomization to death due to any cause, assessed up to 15 years

  2. OS (High risk cohort)

    Stratified log-rank test will be used to compare the OS between the two arms.

    Time frame: From randomization to death due to any cause, assessed up to 15 years

  3. Incidence of adverse events

    Will be measured using the most recent version of the Common Terminology Criteria for Adverse Events.

    Time frame: Up to 30 days after last dose of study treatment

Other outcomes

  1. Estimates of treatment effects by sex

    Estimates of the primary outcome treatment effect and the corresponding 95% confidence intervals (CIs) by sex.

    Time frame: Up to 15 years

  2. Estimates of treatment effects by race

    Estimates of the primary outcome treatment effect and the corresponding 95% CIs by race.

    Time frame: Up to 15 years

  3. Estimates of treatment effects by ethnicity

    Estimates of the primary outcome treatment effect and the corresponding 95% CIs by ethnicity.

    Time frame: Up to 15 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 7, 2026
StartEst.
Dec 4, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07572123
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Dec 4, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Vaishalee P Kenkre
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Nivolumab · Pembrolizumab

Start the discussion